Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Parker Waichman Alonso LLP Files Suit Against Bayer Corporation on Behalf of Woman Injured by the Yaz Birth Control Pill

Tue. September 29, 2009; Posted: 02:36 PM
Stocks RSS
GREAT NECK, N.Y., Sep 29, 2009 (BUSINESS WIRE) -- BAYRY | Quote | Chart | News | PowerRating -- Parker Waichman Alonso LLP filed suit on behalf of a woman who suffered bilateral pulmonary emboli and deep vein thrombosis after taking the Yaz birth control pill. Yaz, as well as its precursor, Yasmin, have been associated with life-threatening adverse events in some women, including heart attacks, blood clots and strokes. The lawsuit was filed in the United States District Court for the Eastern District of New York (Docket No. 1:09-cv-03961).

Anna Butler, a resident of Kansas, first began using Yaz in approximately April 2006 and continued using it through August of 2007 at which time she sustained bilateral pulmonary emboli and deep vein thrombosis resulting in severe and permanent personal injuries, pain, suffering, and emotional distress. Ms. Butler alleges that Bayer Corporation and other named defendants negligently and fraudulently represented that Yaz had been tested and was found to be safe and effective and otherwise concealed their knowledge of its defects. The lawsuit names Bayer Corporation, its subsidiaries, Berlex Laboratories, Inc., and Berlex, Inc. as defendants.

Yaz is the top-selling oral contraceptive in the United States. Last year, Yaz and Yasmin generated approximately $1.8 billion for Bayer. These sales were achieved through a marketing campaign that presented the medications as more than mere birth control pills and touted them as treatments for premenstrual dysphoric disorder, premenstrual syndrome and moderate acne. Bayer Corporation and the other defendants named in the complaint have been warned at least three times by the U.S. Food & Drug Administration (FDA) regarding their misleading television advertisements, which overstate the efficiency of Yaz or Yasmin and minimize the serious risks associated with the drugs.

Yaz and Yasmin are both made with a type of progestin called drospirenone, making them different from many other oral contraceptives. Drospirenone can elevate the body's potassium levels, which can lead to a condition called hyperkalemia in certain patients. Hyperkalemia may result in potentially serious heart and health problems. Adverse Events reported to the FDA involving Yaz and Yasmin include heart arrhythmias, electrolyte imbalance, hyponatremis, hyperkalemia, hyperkalemic arrhythmias, atrial fibrillation, tachycardia, bradycardia, myocardial infarction, stroke, transient ischemic attack, blood clots, embolisms, and sudden death.

On September 26, 2009, the New York Times reported that there are increasing concerns over the safety of Yaz and Yasmin. The article pointed out that two separate Dutch and Danish studies published last month in The British Medical Journal found a higher risk of venous blood clots for women taking newer progestins, including drospirenone. The FDA is currently reviewing the safety of birth control pills with a study designed to identify the incidence of blood clots, stroke and death among users of Yasmin and other oral contraceptives. The Times also reported that Bayer is conducting a postmarketing study comparing the safety of Yaz with other birth control pills.

At least 74 lawsuits have been filed across the country on behalf of victims of Yaz and Yasmin side effects. On September 24, 2009, a hearing was held before the Judicial Panel on Multi-District Litigation regarding a filed petition that requests that all of the Yaz and Yasmin litigation be transferred to a single federal court for centralized and coordinated pre-trial proceedings. A decision on the petition is expected within a few weeks.

Parker Waichman Alonso LLP expects to file many more lawsuits on behalf of Yaz and Yasmin victims in the coming months.

If you or a loved one suffered a heart attack, blood clot or stroke while taking one of these medications, please contact our office by visiting www.yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

About Parker Waichman Alonso LLP

Parker Waichman Alonso LLP is a leading personal injury law firm that represents plaintiffs nationwide. The firm has offices in New York, New Jersey and Florida. Parker Waichman Alonso LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective drugs, medical devices and other products.

For more information on Parker Waichman Alonso LLP, please visit: www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

SOURCE: Parker Waichman Alonso LLP

Parker Waichman Alonso LLP 
David Krangle 
(800) LAW-INFO 
(800) 529-4636 
www.yourlawyer.com
For full details for BAYRY click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [BAYRY]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.